Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference
Kinnate Biopharma, a biopharmaceutical company focused on small molecule kinase inhibitors for challenging genomically defined cancers, announced participation in the Goldman Sachs 42nd Annual Global Healthcare Conference. The event is scheduled for June 10, 2021, at 2:10 PM ET. CEO Nima Farzan will present an overview, and the management team will host investor meetings. A live webcast will be available on Kinnate's website. The company aims to enhance targeted therapeutics for underserved populations using its proprietary Kinnate Discovery Engine.
- None.
- None.
SAN FRANCISCO and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that Nima Farzan, Chief Executive Officer of Kinnate, will provide a company overview at the Goldman Sachs 42nd Annual Global Healthcare Conference, being held virtually from June 8-11, 2021.
Event: Goldman Sachs 42nd Annual Global Healthcare Conference
Location: Virtual
Date: Thursday, June 10, 2021
Time: 2:10 PM ET/ 11:10 AM PT
Members of the Kinnate management team will also host investor meetings during the conference.
A live webcast of the Goldman Sachs presentation will be available in the Investors and Media section of the Kinnate website at www.kinnate.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.
About Kinnate
Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors. For more information, please visit www.kinnate.com.
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements include, without limitation, Kinnate’s expected participation at investor conferences and meetings. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are also intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends. Such expectations and projections may never materialize or may prove to be incorrect. These forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors, including risks related to operating as a preclinical-stage biopharmaceutical company with a limited operating history; our ability to raise additional capital to finance our operations; our ability to discover, advance through the preclinical and clinical development of, obtain regulatory approval for and commercialize our product candidates; the novel approach we are taking to discover and develop drugs; our ability to timely file and obtain approval of investigational new drug applications for our planned clinical trials; the potential for any clinical trial results to differ from our preclinical trial results; negative impacts of the COVID-19 pandemic on our business, including planned clinical trials and ongoing and planned preclinical trials; competition in our industry; regulatory developments in the United States and other countries; our ability to attract, hire and retain highly skilled executive officers and employees; difficulties in managing our growth; our ability to protect our intellectual property; reliance on third parties to conduct our preclinical studies and any future clinical trials, and to manufacture our product candidates; general economic and market conditions; and other risks.
These and other risks, uncertainties, assumptions and other factors are further described under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 filed with the Securities and Exchange Commission (the “SEC”), as well as in our subsequent filings we make with the SEC. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. Investors should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Our forward-looking statements speak only as of the date of this release, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason in the future.
Contacts:
Investors:
Patti Bank
Westwicke, an ICR Company
415-513-1284
investors@kinnate.com
Media:
Colin Sanford
203-918-4347
colin@bioscribe.com
FAQ
What is the date and time of Kinnate's presentation at the Goldman Sachs conference?
Who is presenting at the Goldman Sachs conference for Kinnate?
Will there be a way to watch Kinnate's presentation online?
What is the focus of Kinnate Biopharma's research and development?
How can investors access the recorded webcast after the Goldman Sachs conference?
